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The biodistribution and clearance of
AlbudAb, a novel biopharmaceutical
medicine platform, assessed via PET
imaging in humans
Kevin S. Thorneloe1, Armin Sepp2, Sean Zhang1, Laura Galinanes-Garcia2, Paul Galette1, Wasfi Al-Azzam1,
Danielle J. Vugts3, Guus van Dongen3, Phillip Elsinga4, Johan Wiegers4, Andor W. J. M. Glaudemans4,
Veena Vincent1, Jessica Renaux2, Matt Szapacs1, Mary Birchler1, Matthew Cleveland2, Mats Bergstrom2 and
Marie Davies2*
Abstract
Conjugation or fusion to AlbudAbs™ (albumin-binding domain antibodies) is a novel approach to extend the half-
life and alter the tissue distribution of biological and small molecule therapeutics. To understand extravasation
kinetics and extravascular organ concentrations of AlbudAbs in humans, we studied tissue distribution and
elimination of a non-conjugated 89Zr-labeled AlbudAb in healthy volunteers using positron emission tomography/
computed tomography (PET/CT).
Methods: A non-conjugated AlbudAb (GSK3128349) was radiolabeled with 89Zr and a single 1 mg (~ 15 MBq) dose
intravenously administered to eight healthy males. 89Zr-AlbudAb tissue distribution was followed for up to 7 days
with four whole-body PET/CT scans. 89Zr-AlbudAb tissue concentrations were quantified in organs of therapeutic
significance, measuring standardized uptake value and tissue/plasma ratios. Plasma pharmacokinetics were assessed
by gamma counting and LC-MS/MS of blood samples.
Results: 89Zr-AlbudAb administration and PET/CT procedures were well tolerated, with no drug-related
immunogenicity or adverse events. 89Zr-AlbudAb rapidly distributed throughout the vasculature, with tissue/plasma
ratios in the liver, lungs, and heart relatively stable over 7 days post-dose, ranging between 0.1 and 0.5. The brain
tissue/plasma ratio of 0.025 suggested minimal AlbudAb blood-brain barrier penetration. Slowly increasing ratios in
muscle, testis, pancreas, and spleen reflected either slow AlbudAb penetration and/or 89Zr residualization in these
organs. Across all tissues evaluated, the kidney tissue/plasma ratio was highest (0.5–1.5 range) with highest
concentration in the renal cortex. The terminal half-life of the 89Zr-AlbudAb was 18 days.
Conclusion: Evaluating the biodistribution of 89Zr-AlbudAb in healthy volunteers using a low radioactivity dose was
successful (total subject exposure ~ 10 mSv). Results indicated rapid formation of reversible, but stable, complexes
between AlbudAb and albumin upon dosing. 89Zr-AlbudAb demonstrated albumin-like pharmacokinetics, including
limited renal elimination. This novel organ-specific distribution data for AlbudAbs in humans will facilitate a better
selection of drug targets to prosecute using the AlbudAb platform and significantly contribute to modeling work
optimizing dosing of therapeutic AlbudAbs in the clinic.
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Introduction
Fully human heavy and light chain variable domain
antibodies (dAbs) display good biochemical, biophys-
ical, and antigen-binding affinities [1–3], but their low
molecular weight (10–15 kDa) renders them suscep-
tible to rapid renal clearance that limits their thera-
peutic potential. While this aspect has been overcome
with albumin-binding dAbs, as exemplified by
Exendin-4 AlbudAb demonstrating a reduction in glu-
cose and insulin in humans, very little is known
about the tissue penetration properties of AlbudAbs™
in humans. This information is critical to modeling
tissue concentrations, target engagement, and thereby
making predications for clinical efficacy.
GSK3128349, a member of the AlbudAb platform,
is a light chain dAb with high affinity for human al-
bumin (Kd = 0.85 nM) and can be conjugated or fused
to a therapeutic biologic or small molecule to extend
their plasma half-lives. Albumin is found at high con-
centrations in plasma, but also in extravascular spaces
[4, 5], and therefore AlbudAb tissue distribution is
likely to extend beyond the blood. In combination
with plasma concentration measurements, positron
emission tomography/computed tomography (PET/
CT) [6–8] provides the capability to explore not only
the steady-state, but importantly also the kinetics of
AlbudAb extravasation. Understanding the kinetics
provides the opportunity to assess the turnover of
AlbudAb in extravascular organ compartments, and
estimate the level of target engagement with respect
to dose and time [9].
Positron emission tomography (PET) imaging of
proteins requires measurement of a slower tissue
penetration rate and longer plasma exposure than
typical for small molecule drugs. Proteins do not dif-
fuse across plasma membranes and extravasation pre-
dominantly takes place via paracellular pores.
Zirconium-89 (89Zr), with a half-life of 3.3 days, is
therefore a radiolabel of choice for protein PET stud-
ies, remaining detectable for up to 10 days even at
the low dose levels which are deemed appropriate in
clinical studies [10, 11]. Protein labelling methods for
89Zr utilize conjugation of desferrioxamine derivates
and form very stable Zr complexes [10, 12, 13] .
In the present study, we administered
89Zr-GSK3128349 AlbudAb to eight healthy male vol-
unteers and used a combination of PET/CT, scintilla-
tion counting, and mass spectrometry in an adaptive
design to follow the time course of AlbudAb tissue
and plasma concentrations simultaneously. These re-
sults will facilitate quantitative insight into target ac-
cessibility for AlbudAbs across various human organs




Eight healthy male participants between 50 and 65 years
of age were enrolled. The higher age range was moti-
vated to limit lifetime cancer risk from radiation expos-
ure, as outlined by the International Commission on
Radiological Protection [11]. The body mass index
(BMI) for the participants ranged between 19.0 and
31.0 kg/m2, with full details given in the Additional file 1.
The study was approved by the appropriate regulatory
and ethics committees (UMCG Medisch Ethische Com-
missie, Groningen, Netherlands) as required, and con-
ducted in accordance with the International Conference
on Harmonization for Good Clinical Practice and the
principles of the Declaration of Helsinki. It was moni-
tored by an Internal Safety Review Committee. Informed
consent was obtained from all individual participants in-
cluded in the study. The study was listed on Clinical-
Trials.gov (NCT02829307).
AlbudAb production and radiolabeling
GSK3128349 was manufactured and tested to ensure
quality, identity, potency, and safety in accordance with
current GSK Good Manufacturing Practices (cGMP).
89Zr was coupled to unlabeled GSK3128349 via the bi-
functional chelate desferal at the VU University Medical
Center [13]. See Additional file 1. Procedures for radiola-
belling of GSK3128349 with 89Zr were validated with re-
spect to stepwise quality controls and assessment of
final product quality. A single batch of GSK3128349 was
used for production of all 89Zr-GSK3128349 radiolabeled
batches.
89Zr-GSK3128349 was diluted with unlabeled
GSK3128349 to achieve a specific activity of 15 MBq/
mg, with the 89Zr-GSK3128349 constituting around
0.015% of the total 1 mg GSK3128349 protein adminis-
tered. A 1 mg total dose was utilized, as based on the
pharmacokinetic properties of GSK3128349 it was
deemed the minimum dose required to enable measure-
ment of GSK3128349 plasma concentrations by mass
spectrometry.
Study design
Participants were screened up to 28 days before entering
the clinic, when on day 1 a single intravenous (IV) dose
of 1 mg of 15 MBq/mg 89Zr-GSK3128349 was adminis-
tered (Additional file 1: Figure S1). Participants were dis-
charged from the clinic on day 2, and overall underwent
four PET/CT scans within the 7-day post-dose period.
Multiple blood samples were taken for up to 42 days
post-dosing to analyze plasma radioactivity, GSK3128349
concentration, and presence of anti-GSK3128349
antibodies.
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Using data from the first two individuals, the organ
and whole-body radiation exposure was calculated using
OLINDA software to confirm that the effective doses
were below 10 mSv (as outlined by the International
Commission on Radiological Protection) [11]. As a re-
sult, no reduction in administered radioactivity was
deemed necessary for the remaining six participants.
Anonymised individual participant data and study docu-
ments can be requested for further research from www.
clinicalstudydatarequest.com.
PET procedures and analysis
The exact amount of administered radioactivity was de-
termined by measurements of the injection syringe be-
fore and after administration. The IV infusion of 10 mL
was administered over approximately 20 min. All scan-
ning and blood sampling times refer to start of the
infusion.
The PET scanning performed from head to mid-thigh
was done using two EARL accredited Biograph mCT 64
slice PET/CT systems from Siemens, Knoxville, USA.
The scanning time per bed position was typically 5 min
but increased to 9 min in the later scans to enhance de-
tection. Images were reconstructed with full corrections
for attenuation and scatter, including a post-processing
filter of 6.5 mm giving a resolution of 7 mm. The recon-
structions were done including PSF (point-spread func-
tion) and TOF (time-of-flight) and conform to the
current EARL specifications. The low-dose CT was per-
formed at each PET scanning session for attenuation
correction with settings to allow for no more than
0.5 mSv per session.
In the PET images, volumes of interest (VoI) were out-
lined in the major organs, using an ellipsoid fitting inside
the organ, avoiding border effects. The average radio-
activity concentration was determined and represented
as SUVmean (SUV corrected for injected radioactivity
and body weight). For smaller organs or structures, the
principle of SUVpeak was applied, averaging over a
sphere of 1 cm3. For some organs with uncertain visibil-
ity in the PET images, the delineation was aided by the
CT scan. All SUV values were decay corrected to the
start time of tracer administration.
The lowest theoretical value for the tissue-plasma ratio








, where VP, org is the organ plasma volume and Vorg the
total volume. The highest theoretical value for the
tissue-plasma ratio ðtpÞmax corresponds to the situation
where the interstitial concentration is equal to that in
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, where VI, org is the organ interstitial volume. All re-
spective volume values were taken from the parameter
set compiled by Shah and Betts [14].
Pharmacokinetics
Plasma samples were collected for the first two subjects
and encompassed pre-dose, 1, 3, 6, 8 h and 1, 2, 3, 5,
and 12 days after administration, respectively, and ana-
lyzed using gamma counting and liquid chromatography
tandem mass spectrometry (LC-MS/MS) for quantita-
tion of GSK3128349. Additional samples were taken at
19, 30, and 43 days, but only analyzed with respect to
total GSK3128349 using LC-MS/MS. The timing of the
blood sampling for the remaining subjects was modified
as determined most appropriate from observation of
data from the first two subjects. Blood samples were al-
ways taken in conjunction with PET scanning.
89Zr-GSK3128349 plasma radioactivity was measured in
a well counter cross-calibrated with the camera and
decay corrected to the start of administration. Plasma
concentrations of total GSK3128349 were determined by
trypsin digestion and solid-phase extraction of the spe-
cific LLILAFSR peptide fragment derived from the Albu-
dAb complementarity determining region, which was
quantified by LC-MS/MS analysis [15].
Cumulative urine was collected for the first 24 h
post-dosing to determine the percent of administered
radioactivity recovered in urine. If the total amount of
radioactivity excreted in urine exceeded 3% for the first
two subjects, then further discrete urine samples would
be taken for subsequent subjects.
Non-compartmental analysis (NCA) of the plasma
pharmacokinetics of both 89Zr-labeled as well as un-
labeled GSK3128349 AlbudAb was performed using
Matlab 2017b SimBiology v5.7.
Safety and immunogenicity
Physical examinations, medical history, ECG, and clinical
laboratory measurements were performed before and
after dosing GSK3128349 on day 1 and on day 2. Rou-
tine hematology, serum chemistry, and urine analysis
were performed on day − 1, 2, 6, 13 (± 1), 20 (± 2), and
21 (± 2). The presence of antibodies to GSK3128349 was
assessed using an analytically validated bridging electro-
chemiluminescent (ECL) immunoassay. Briefly, serum
samples collected on day 1 (before dosing) or day 43 (±
2; post dosing) were incubated for 1 h with biotinylated
GSK3128349 and sulfo-TAG-labeled GSK3128349 before
addition to a streptavidin-coated MSD plate. After 1 h,
the plate was washed (PBS-tween) and read on a MSD
Sector Imager Reader 600. Normal human serum and
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serum spiked with an anti-IgG (Vk) mAb were included
as negative and positive controls, respectively.
Results
Subjects and safety
Eight subjects were enrolled into the study (Table 1),
with inclusion/exclusion criteria listed in the Additional
file 1. The mean administered radioactivity was 14.0 ±
0.9 MBq (range, 12.77–15.03 MBq). The effective dose
from administered radioactivity for the first two subjects
were 5.4 and 7.5 mSv, which together with four low dose
CT scans (0.5 mSv/scan) gave total effective radiation
doses of 7.4 and 9.5 mSv. The average radiation expos-
ure across all study subjects was 0.448 mSv/MBq, with a
mean subject exposure of 8.3 mSv.
89Zr-GSK3128349 was well tolerated and no adverse
events related to the AlbudAb were observed in any of
the subjects. No observed changes in vital signs, labora-
tory results, or electrocardiograms were deemed clinic-
ally significant. One subject was found to have
pre-existing anti-GSK3128349 antibodies at the start of
study. In this subject, the titres were low and similar at
follow-up, suggesting that these anti-GSK3128349 anti-
bodies were not related to dosing. None of the subjects
developed anti-GSK3128349 responses during the study.
PET/CT images
As expected, the PET/CT images demonstrated an initial
dominant vascular distribution, highlighted by signals in
cardiac blood pools and large vessels. This was particu-
larly pronounced in images acquired shortly after dosing
(Fig. 1). A gradual increased contrast between the kid-
neys and the rest of the body developed over time.
Transaxial images demonstrated a punctate signal, which
may reflect noise arising from the low dose of label or
local vasculature, as in the study 89Zr-GSK3128349 con-
centration in the blood always exceeded the tissue con-
centrations, except for prominent uptake in the renal
cortex. Features of major organs were still identifiable,
as shown for the heart, kidneys, liver, and spleen (Fig. 2).
Particularly, the heart chambers and aorta were clearly
visible.
Standardized uptake values
The mean standard uptake values (SUV) measured by
PET/CT characterize the concentration of
89Zr-GSK3128349 in the region of interest (ROI) relative
to the body average. The mean SUVs ranged from very
low values in brain and muscle to high values in blood
pools and renal cortex (Fig. 3). In most organs, except
muscle and renal cortex, there was a decrease with time.
Organ time-activity data across all subjects suggest that
tissue distribution steady state is achieved within ap-
proximately 100 h after dosing.
Plasma pharmacokinetics
The maximal plasma concentration of GSK3128349 oc-
curred in the first sample drawn at 60 min (390 ± 60 ng/
mL), suggesting an initial volume of distribution around
2.5 L, close to that of the plasma volume in humans.
The plasma pharmacokinetics of 89Zr-GSK3128349 mea-
sured by scintillation, and of total GSK3128349 mea-
sured by mass spectrometry, followed a biexponential
time course (Fig. 4, radio pharmacokinetics (PK)
decay-corrected for the 89Zr). We found the variation
between subjects was small, with only one outlier (at
288 h) excluded from the analysis as it deviated from the
mean by 8.4 standard deviations. The initial distribution
(alpha) phase, during which the plasma concentration
reduced relatively rapidly, lasted for approximately
100 h, and reflects extravasation of the dosed protein
into organ interstitial spaces. The beta phase with slower
decline was described by first-order kinetics, and charac-
terized as the plasma elimination half-life.
The pharmacokinetic parameters, established through
non-compartmental analysis, are presented in Table 2
(and Additional file 1: Table S2). The mean volume of
distribution at steady state (Vss) and clearance were 5.4
± 1.2 L and 9.7 ± 1.6 mL/h, respectively. The terminal
half-life of the GSK3128349 AlbudAb was estimated as
Table 1 Eight Caucasian male subjects were enrolled into the study. All subjects had four PET/CT scans, except subject 122 who
declined further participation after the first two scanning sessions for availability reasons
Subject Age (years) Weight (kg) BMI (kg/m2) Dose of radioactivity (MBq)
105 54 76.1 25.7 12.77
110 53 72.2 22.8 14.53
122 54 68.6 23.5 14.24
123 60 92.3 27.6 13.27
125 53 91.8 27.4 14.64
127 56 70.2 21.4 14.72
132 54 73.0 20.9 15.03
135 56 83.1 23.3 13.06
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422 ± 40 h (17.5 ± 1.7 days); strikingly similar to human
albumin [16].
Urine excretion of radioactivity
The cumulative urine radioactivity obtained during the
24 h after 89Zr-GSK3128349 infusion contained a total
of 3.8 and 4.0% of administered radioactivity in the first
two subjects. Since 3% in the first two subjects was dic-
tated per protocol as the threshold to initiate further
urine sampling, further urine collection (single void
samples) was performed in all subsequent subjects.
89Zr-GSK3128349 urinary concentration in samples col-
lected beyond 24-h post-dose was about one-third of
that in the first 24 h sample (average concentration on
day 1 was 495 ± 268 Bq/mL and 178 ± 142 Bq/mL on
day 6).
Tissue-to-plasma ratios
The tissue-to-plasma (t/p) radioactivity concentration
ratios for each organ (Fig. 5) predominantly characterize
the process of 89Zr-GSK3128349 AlbudAb extravasation
into interstitial organ spaces. The ratio can change in
time, reflective of the rate of the process. We plotted the
measured t/p levels from the current study along with
the minimal (if the label was confined to the vasculature
only) and maximal (if label concentration in organ inter-
stitial space was equal to that in plasma) expected ratios,
based on work by Shaw and Betts [14].
We found that in the case of lungs, liver, and spleen,
the highest expected t/p ratio was reached quickly, and
remained high for the duration of the study, suggesting a
rapid distribution of AlbudAb into interstitial spaces in
lung, liver, and spleen. In contrast, in brain, the
tissue-plasma ratio remained at the theoretical minimum
level throughout the study, suggesting that the AlbudAb
remained predominantly confined to the brain
vasculature.
For numerous organs, the tissue-plasma ratios in-
creased with time, reflecting time-dependent extravasa-
tion. Organs in this group were thigh muscle, parotid
gland, pancreas, and bone marrow.
Finally, in a few cases, the observed t/p ratio exceeded
the theoretical maximum. In heart measurements, the
observed value of around 0.5 was significantly higher
than the maximal predicted value, being instead closer
to that expected for blood. This is expected given that
the ROI encapsulated the entire organ including blood
present in the heart chambers. In the case of kidneys,
the initial value is close to the expected maximum but
continues to increase, demonstrating predominance in
the cortex. Finally, we also observed significant radiola-
bel accumulation beyond the theoretical maximum in
testis.
Discussion
The small size of antibody fragments delivers the benefit
of improved tissue penetration [17, 18], but also renders
them sensitive to rapid renal elimination [19]. Members
of the AlbudAb platform, such as GSK3128349, have
been engineered to bind albumin with high affinity in
Fig. 1 Maximum intensity projections (MIP) obtained at different time points after administration for one representative subject 135. MIP images
for additional subjects 105 and 127 are provided in the Additional file 1: Figures S2 and S4
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several species including humans, and can be genetically
fused or chemically conjugated to therapeutic agents
(examples include a domain antibody against tumor ne-
crosis factor receptor 1 [20] and apelin [21] as well as
the exendin-4 AlbudAb which demonstrated an ability
to reduce glucose and insulin in humans [22]). Given
that many therapeutic targets are expressed as cell mem-
brane receptors on tissue-embedded cells not exposed
directly to plasma, and that GSK3128349 binds albumin
also present in the interstitial fluid and lymph, AlbudAbs
likely extravasate into organs of the body. To this end,
the current PET/CT study of 89Zr-GSK3128349 in
humans has provided a unique insight into the distribu-
tion properties of the AlbudAb platform into various
organs. Due to the size of the AlbudAb-albumin com-
plex, the extravasation is likely to be dominated by filtra-
tion, like in the case of antibodies [23]. The rate of the
process varies from rapid in organs with leaky vascula-
ture (liver, spleen) to slow or imperceptible in the brain.
It is likely that the properties of the AlbudAb and albu-
min will outweigh those of any future potential thera-
peutic payload, i.e., the drug will remain extracellular
and will not diffuse across the plasma membrane. The
PK of an AlbudAb conjugated with a therapeutic may
well be affected by target-mediated disposition if mem-
brane proteins are targeted by the therapeutic agent.
More quantitative descriptions of tissue penetration and




Fig. 2 Transaxial images (top PET, bottom PET/CT fused images) across the a heart, b kidneys, and c liver/spleen from the same subject 135
presented in Fig. 1. Times post dose 7, 79, 120, and 168 h post dose. Additional transaxial images for additional subjects 105 and 127 are
provided in the Additional file 1: Figures S3 and S5
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Fig. 3 The SUV time course data for [89Zr]-GSK3128349 tissue distribution. Individual subjects are identified by the color. While some organs
could be measured as whole organs (e.g., kidneys, liver, and spleen), some could only be sampled in part (e.g., muscle and lungs). Subject 105-
light blue, 110-orange, 122-gray, 123-yellow, 125-purple, 127-green, 132-dark blue, 135-brown
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therapeutic AlbudAbs within the framework of physiolo-
gically based pharmacokinetics [14, 19, 23].
This study included four adaptively modified PET/CT
scan time-points per subject that yielded tissue penetra-
tion and elimination PK using only eight subjects.
Plasma concentration time course data obtained via
LC-MS/MS compared to radiolabel PK yielded very
similar results, suggesting that the presence of the radio-
label (on only ~ 0.015% of the molecules dosed) does
not affect the tissue distribution properties of
GSK3128349. The initial volume of distribution (calcu-
lated from the plasma Cmax) was very close to human
plasma volume, indicating that the IV dose is rapidly di-
luted in the circulation after dosing. A process signifi-
cantly faster than the subsequent tissue distribution
phase reaching steady-state in about 100 h, similar to
that reported for albumin [16] and other large proteins
such as intact monoclonal antibodies [24]. The 5.5 L
steady-state volume of distribution for GSK3128349 is
also typical for monoclonal antibodies whose distribu-
tion is unaffected by target-binding [25, 26]. Finally, the
terminal half-life of GSK3128349 of 17.5 days is close to
the 18–19 days reported for human albumin [27], imply-
ing that AlbudAb remains bound to albumin during
endosomal recycling [28] and hence probably shares the
albumin elimination pathway. Overall, the AlbudAb
plasma kinetics properties described here are very simi-
lar to that of albumin, suggesting that the current Albu-
dAb PET study data may provide an indirect assessment
of albumin distribution.
T/p ratios for several organs are significantly higher
than expected from their respective organ vascular
spaces alone but are instead more consistent with a
summed combination of vascular and interstitial spaces.
Although t/p ratios did not always reach a level to sug-
gest a similar concentration in the vascular and intersti-
tial compartments, this observation is consistent with
Wiig et al. and Gyenge et al. [29–31] who have shown
that there is an “exclusion space” in tissue on the order
of 16–26% for albumin and antibodies, whereby a por-
tion of the interstitial space is not accessible. “Exclusion
space” estimates have only been made for a few organs,
therefore our comparisons have used the estimated max-
imum t/p ratios (Fig. 5) based on an assumption that
GSK3128349 can distribute into the full interstitial space
with a concentration equal to that in plasma. However,
filtration at the vascular barrier is expected to reduce
the interstitial concentrations of plasma proteins in or-
gans with continuous and fenestrated capillaries [32]. In
addition, there can be a reduction in interstitial tissue
volume for larger proteins, and therefore, the actual
highest attainable t/p ratios could be lower than that
presented herein. Consistent with this, the steady-state
Fig. 4 Plasma PK of [89Zr]-GSK3128349 as detected by radio PK (red circles), and total GSK3128349 as detected by LC/MS (blue circles). Each dot
represents data for a single time point from a single subject
Table 2 Plasma pharmacokinetic parameters for total
GSK3128349
AUC (0-inf) CL MRT T½ V_ss
(ng/mL)*h mL/h h h mL
Min 81,900 7.8 483 360 4344
Max 128,598 12.2 657 477 6060
Median 97,904 10.2 562 428 5862
Mean 105,482 9.7 565 422 5434
STDEV 17,508 1.6 55 38 696
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volume of distribution measured in this study for
GSK3128349 is twofold higher than the plasma volume,
whereas the entire extravascular volume exceeds that of
plasma by about fourfold, suggesting that GSK3128349
achieves around a two- to fourfold dilution during the
extravasation process.
The data reported here suggest that GSK3128349 has a
rapid access to the tissue interstitium in some organs (e.g.,
lung and liver due to fenestrated endothelium) and is virtu-
ally excluded from others (e.g., brain by the properties of
the blood-brain barrier). The t/p ratio time course for
89Zr-GSK3128349 increases with time in several organs—
especially noticeable in muscle, renal cortex, bone marrow,
parotid gland, testis, and spleen which is likely to reflect the
penetration of GSK3128349 into the interstitial space in
these organs. The data are not sufficient to elucidate the
exact mechanism for transfer from plasma to interstitium,
but GSK3128349 bound to albumin can be expected to be
transported across the capillary endothelium by filtration
and diffusion, as described within the framework of
two-pore hypotheses of extravasation [32].
PET measures the total tissue concentration of 89Zr,
comprised of both the intact 89Zr-GSK3128349 protein
in both vascular and interstitial spaces, as well as any
potential 89Zr-containing degradation products due to
the residualizing nature of the label. This is likely to be
especially relevant in the case of kidneys, where the cel-
lular uptake and catabolism of 89Zr-GSK3128349, as well
as specific uptake and intracellularly retention of any re-
sidual free 89Zr, can lead to accumulation of the label
[33, 34] and contribute to the overall signal.
We observed high PET signal in kidneys with an aver-
age final SUV of approximately 9, and even higher levels
in the cortical region. The kidneys constitute less than
1% of body weight, indicating that the fraction of admin-
istered radioactivity captured by the kidneys is about 9%.
At the same time, we found 3–4% of the administered
radioactivity in the initial 24-h urine, which is the typical
daily range for albumin passing through the glomerular
barrier in humans [35]. Most protein found in urine is
thought to be endocytosed via megalin-cubilin-mediated
uptake in the proximal tubules of the renal cortex and
to be degraded [35]. Our imaging data, which indicate
significant accumulation of 89Zr in the renal cortex are
in agreement with this given the residualizing nature of
Fig. 5 Tissue-to-plasma ratios for different organs across time points
for all subjects. The light gray dashed horizontal line denotes the
estimated tissue-plasma ratio if the label was confined to the
vasculature only. The dark gray horizontal dashed line denotes an
estimation for when the label concentration in organ interstitial
space is equal to that in plasma. Subject 105-light blue, 110-orange,
122-gray, 123-yellow, 125-purple, 127-green, 132-dark
blue, 135-brown
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89Zr label. Importantly in support of this residualization
hypothesis, no such renal accumulation is observed in
pre-clinical species, when the AlbudAb is conjugated to
a non-residualizing radioisotope, e.g., 3H ([17] & manu-
script in preparation). Nevertheless, we cannot eliminate
the possibility that the dosed sample contained a small
amount of free label which may have been rapidly re-
moved in the kidneys and in part retained and passed on
to urine soon after dosing.
Our attachment of 89Zr to the GSK3128349 AlbudAb
can be considered as representative of a therapeutic pay-
load that could be replaced instead by other protein do-
mains through genetic fusion, or by coupling of peptides
or even small molecule drugs. One advantage of Albu-
dAbs compared with full sized antibodies is that around
a tenfold higher molar concentration can be achieved
following the same mg/kg dose due to their relatively
low molecular weights. This advantage can be critically
important, particularly if a target of interest resides in a
difficult to reach tissue compartment.
Extending the plasma half-life of small molecule drugs
by conjugation of an AlbudAb also offers the option of
maintaining required plasma exposures at much lower
doses of active compound than otherwise possible; po-
tentially reducing the risk of systemic toxicity driven by
higher peak plasma concentrations, more frequent dos-
ing and increased total dose administered.
The nature, location, concentration, and the turnover
of the therapeutic target can also be expected to affect
both the kinetics and tissue concentrations of
AlbudAb-based therapeutics. While no major deviations
from the described AlbudAb PK and tissue distribution
would be expected in the case of soluble targets, in the
case of binding to cell surface proteins, one would ex-
pect to see target-mediated disposition, just like for con-
ventional monoclonal antibodies. An understanding of
the distribution of the unconjugated AlbudAb, as pro-
vided here through PET imaging, can now be incorpo-
rated with the understanding of target-mediated
disposition activities of specific targets of interest to
model target engagement of candidate therapies in sup-
port of both discovery and development efforts.
Conclusions
The study has confirmed the utility of 89Zr-immuno-PET
as a versatile method to explore tissue distribution and
organ access for proteins, demonstrating that it is possible
to conduct an immuno-PET study in healthy volunteers
at radiation exposure below 10 mSv. The average
administered radioactivity of 14 MBq was very low but
generated adequate images and reasonable quantitative
information up to 7 days after administration allowing
measurements of tissue penetration and elimination PK
of 89Zr-GSK3128349.
The free fraction of GSK3128349 AlbudAb is expected
to be in the region of ≈ 0.002% in plasma and in these
conditions GSK3128349 acquires albumin-like properties
in circulation and in organ extravascular compartments.
These data contrast with shorter residence times ob-
served for other similarly sized dAbs and smaller pro-
teins that do not bind albumin and can be eliminated
within hours by renal filtration.
The study also demonstrated significant differences
between organs in respect of the kinetics of
GSK3128349 AlbudAb extravasation, indicating that
steady-state exposure in different organs may be differ-
ent from that achievable with single doses. The results
suggest rapid access to tissue interstitium in the liver,
lungs, spleen, bone marrow, and other organs, with no
extravasation and accumulation in the brain. Hence, the
albumin-binding and distribution properties suggest that
GSK3128349 has the potential to be a useful platform to
carry therapeutic payloads to access tissues (with excep-
tion of CNS) with desirable pharmacokinetics.
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